Company Research Report: Rune Labs

Company Overview

Name: Rune Labs

Mission: Rune Labs aims to be a leader in precision neurology, specifically focusing on using data to revolutionize patient care and unlock disease-modifying therapies for neurodegenerative disorders such as Parkinson’s Disease.

Founded: October 2018

Founders: No information is available

Key People:

Brian Pepin, CEO and Founder

Swati Reichmuth, Chief Operating Officer and Chief Financial Officer

Ram Balasubramanian, VP Engineering

Priya Kumar, VP of Communications and Marketing

Ro'ee Gilron, Lead Neuroscientist

William Newby, VP of Product

Chase Babcock, VP of Operations, StrivePD

Aiden Arnold, Senior Data Scientist

Adin Stein, Chief Information Security Officer

Headquarters: 1314 8th Ave, San Francisco, CA 94122

Number of Employees: No information is available

Revenue: No information is available

Known For: Rune Labs is known for its StrivePD ecosystem which utilizes the Apple Watch to collect Parkinson's symptom data, helping clinicians and patients manage and monitor the disease more effectively.

Products

StrivePD

Description: A care delivery ecosystem specifically for Parkinson’s disease.

Key Features:

Personalized symptom summaries and data-enriched care workflows for clinicians.

Custom workflows for advanced therapies.

Symptom and medication tracking via the Apple Watch and patient app.

Connection of patients to clinical trials to facilitate comprehensive care management.

StriveStudy

Description: A cloud-based clinical trials platform providing comprehensive solutions for data collection and enriched recruitment with GCP compliance.

Key Features:

Baseline and long-term data collection.

Development of novel digital biomarkers.

Improved patient compliance and support throughout clinical trial processes.

Recent Developments

Product Launches and Updates

StriveStudy Platform: Launched in March 2023, this platform is aimed at accelerating the development of precision neurology therapies.

Rune Labs Launches GenAI Clinical Support: Announced to enhance care management for Parkinson’s patients and clinicians.

FDA Clearances

FDA 510(k) Clearance: Rune Labs secured FDA clearance in June 2022 for its StrivePD ecosystem on Apple Watch, marking a significant milestone in digital health for Parkinson’s Disease.

Partnerships

Collaboration with BlueRock Therapeutics: Engaged to better characterize Parkinson's disease state in cell therapy trials.

Partnership with Aspen Neuroscience: Collaborated to deeply characterize symptom activity in Parkinson’s Disease for upcoming trial-ready cohort screening studies, announced in August 2023.

Collaboration with Coastal Research Institute: Initiated to identify biomarkers of Multiple Sclerosis lesions using AI platforms to analyze patient neurophysiological data, announced in July 2022.

Strategic Rounds

Series A Funding: Raised $22.8 million led by Eclipse Ventures in September 2021.

Strategic Investment: Announced a $12 million strategic round led by Nexus NeuroTech Ventures in January 2024 to accelerate the adoption of novel Parkinson’s technologies.

Industry Recognition and Involvement

National Plan to End Parkinson's Disease: Rune Labs publicly supported the signing of this plan, showcasing an active engagement in advocacy efforts for Parkinson's Disease awareness and research.

Conclusion

Rune Labs is a burgeoning leader in the field of precision neurology dedicated to transforming patient care through data-driven methods, primarily focusing on neurodegenerative diseases such as Parkinson’s. With significant FDA clearances, product innovations, strategic partnerships, and funding rounds, the company is well-positioned to continue its growth and influence in the health tech landscape.